Type 1 Diabetes Treatment Companies

Top Industry Leaders in the Type 1 Diabetes Treatment Market

Latest Type-1 Diabetes Treatment Companies Update

• 
  November 2023: Eli Lilly and Company's Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind to activate both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) hormone receptors, was approved by the U.S. FDA. Adults who are overweight (with a BMI of 27 kg/m2 or higher) or have weight-related medical conditions including hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease and are obese (with a BMI of 30 kg/m2 or higher) are prescribed Zepbound with the intention of achieving and maintaining weight loss. It should be utilized in conjunction with an increased level of physical activity and a reduced-calorie diet. Zepbound is contraindicated in conjunction with other products containing tirzepatide or GLP-1 receptor agonists. Additionally, its safety in patients with a prior diagnosis of pancreatitis or severe gastrointestinal disease, such as gastroparesis, has not been investigated.

• 
  March 2023: Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has made a recent announcement regarding the approval of the Investigational New Drug Application (IND) by the U.S. FDA for VX-264. This drug is an immunoprotective device encapsulated fully differentiated pancreatic islet cells derived from stem cells and developed by Vertex. VX-264 has the potential to be utilized in the treatment of type 1 diabetes (T1D). The VX-264 program does not necessitate the administration of immunosuppression, potentially expanding the demographic of individuals with T1D who could benefit from this experimental treatment. Vertex intends to commence a Phase 1/2 clinical trial examining the safety, tolerability, and efficacy of VX-264 in patients with T1D during the initial six months of 2023. Health Canada previously granted approval to the company's Clinical Trial Application (CTA) for VX-264; in Canada, the Phase 1/2 trial is currently in progress.

• Astellas Pharma (Japan)


• Eli Lilly (US)


• Merck (US)


• Novo Nordisk (Denmark)


• Sanofi (France)


• AstraZeneca (UK)


• Boehringer Ingelheim GmbH (Germany)


• Novartis (Switzerland)


• Pfizer Inc. (US)


• Abbott Laboratories (US)


• Mannkind Corporation (US)


• Braun Melsungen AG (Germany)